COYA: Coya Price to Sales

Corporate company logo of Coya (COYA)

Coya Therapeutics, Inc. (COYA) develops cellular therapies for neuropathologies, leveraging robust cold chains and diversified manufacturing facilities. The price-to-sales ratio reflects market expectations, where the 14.90 indicator expresses the state of the metric. Despite the risks of component logistics disruptions due to global conflicts, the humanitarian status of developments in the US ensures research stability and protection from sanctions.

COYA: coyatherapeutics.com P/S Multiple 03/21/2024 - 11/17/2026

Analytical breakdowns for Coya Therapeutics, Inc. (COYA)

Summary company analytics:COYA coyatherapeutics.com
Flagship merchandise of Coya

The stability of Coya Therapeutics, Inc. (COYA) relies on partner co-financing for the development of drugs targeting ALS and Alzheimer's disease. The P/S ratio relates market capitalization to annual sales volume, measuring the premium investors place on current revenue. By analyzing the company's P/S level, one can identify whether the asset is undervalued or if there is a risk of inflated expectations regarding clinical scaling. This metric allows for the determination of the business's fair value during the early growth stage.

Who Coya Therapeutics, Inc. competes with

BIIB (Biogen) - Market Capitalization-to-Revenue Ratio|P/S Multiple NBIX (Neurocrine Corp)|Regencell Bioscience - Price-to-Revenue Ratio|Axsome Therapeutics - P/S Multiple|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Price-to-Revenue Ratio|Price to Sales Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - P/S Multiple|CPRX: Market Capitalization-to-Revenue Ratio|P/S Multiple DNLI|Price-to-Revenue Coefficient Harmony Biosciences|Biohaven Ltd - Market Cap to Revenue|P/S Multiple Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Market Cap to Revenue|Price-to-Revenue Coefficient Praxis Corp PRAX|AVXL: P/S Multiple|CBLL (ceribell.com) - Price-to-Revenue Ratio|PRTA (Prothena Corporation) - P/S Multiple|Market Cap to Revenue alector.com (ALEC)|Price-to-Revenue Ratio Annexon, Inc. (ANNX)|OMER - Price to Sales|P/S Multiple NGNE (Neurogene Inc)|AC Immune (ACIU) - Price to Sales|Voyager Therapeutics Inc - P/S Multiple|Neumora (NMRA) - Market Cap to Revenue|SCLX: P/S Multiple|TVGN - Price-to-Revenue Coefficient|ACOG (Alpha Cognition Inc) - P/S Multiple|Market Cap to Revenue cogrx.com (CGTX)|Price-to-Revenue Ratio Inhibikase Therapeutics Inc (IKT)|Price-to-Revenue Coefficient Cassava Sciences|P/S Multiple ASRT (Assertio Holdings)|Market Cap to Sales Volume VTGN (VistaGen Therapeutics Inc)|OVID: Market Cap to Revenue|ABOS: Price-to-Revenue Ratio|CervoMed (CRVO) - Price-to-Revenue Ratio|Price to Sales Alterity Therapeutics Ltd (ATHE)|CLNN (Clene) - P/S Multiple|Market Cap to Revenue Ratio PEPG (PepGen)|Market Cap to Revenue JUNS (Jupiter Neurosciences, Inc.)|P/S Multiple relmada.com (RLMD)|Price-to-Revenue Ratio Annovis Bio Corp ANVS|GRCE: Market Cap to Revenue Ratio|AIFF - Price-to-Revenue Ratio|KLTO (anewmeds.com) - Market Cap to Revenue Ratio|NRSN (NeuroSense Therapeutics Ltd.) - Market Cap to Revenue|revivapharma.com - Market Capitalization-to-Revenue Ratio|MTVA (metaviatx.com) - P/S Multiple|NRXS: Market Capitalization-to-Revenue Ratio|P/S Multiple HSDT|PASG - Price to Sales|P/S Multiple NEUP (Neuphoria Therapeutics)|NERV: Market Cap to Revenue Ratio|ATHA: Market Cap to Revenue|Addex Therapeutics Ltd - Market Cap to Sales Volume|Alzamend Neuro, Inc. (ALZN) - Price-to-Revenue Ratio|CYCN (Cyclerion Therapeutics Inc.) - Price-to-Revenue Ratio|Market Cap to Revenue PTIX|KTTA: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue CRGT (Cortigent Medical)|ATXI (Avenue Therapeutics, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Brainstorm Cell Therapeutics, Inc. BCLI|Market Capitalization-to-Revenue Ratio CARA|chromocell.com - P/S Multiple|Price-to-Sales Ratio ELYM|ITCI: P/S Multiple|Price to Sales Longboard Pharmaceuticals, Inc. (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGN: Market Capitalization-to-Revenue Ratio|P/S Multiple NRBO|SAGE: Price-to-Sales Ratio|Synaptogenix Inc. - Market Cap to Revenue|Market Cap to Sales Volume TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - P/S Multiple|Anew Medical (WENA) - Market Cap to Revenue|CERE (Cerevel Corp) - Market Cap to Revenue